Day 13 of 30 •
•
~4 min read

NEC in Numbers: Statistics That Matter

Examining the clinical data, incidence rates, and survival statistics of neuroendocrine neoplasms.

#statistics #neuroendocrine cancer #epidemiology #data #research

Behind every statistic is a human life—a mother, a father, a daughter, a friend. While numbers cannot capture the depth of a family’s emotional experience, examining clinical data is essential to understanding the scope of the neuroendocrine cancer crisis and directing resources where they are needed most.

Here are the key numbers that define neuroendocrine neoplasms today:

1. Incidence and Prevalence

  • 2% of all cancers: Neuroendocrine neoplasms make up roughly 2% of all diagnosed cancers in the United States, with approximately 12,000 new cases diagnosed each year.
  • Substantial Rise in Diagnoses: The reported incidence of neuroendocrine tumors has increased more than sixfold over the last four decades. This rise is attributed both to improved cross-sectional imaging (CT, MRI) and greater clinical awareness, though many cases remain undiagnosed.
  • High Prevalence: Because well-differentiated NETs often have prolonged survival times, the prevalence (number of people living with the disease at any given time) is high—second only to colorectal cancer among gastrointestinal malignancies.

2. High-Grade Carcinomas (NEC)

  • 10% to 15% of Neoplasms: Poorly differentiated high-grade neuroendocrine carcinomas account for only a small fraction of all neuroendocrine cases.
  • Ki-67 Proliferation: While Grade 1 NETs have a Ki-67 index of less than 3%, high-grade NEC frequently demonstrates a Ki-67 index exceeding 60% to 90%, signifying rapid, aggressive cell division.
  • Diagnostic Delay: The average patient with a neuroendocrine neoplasm experiences symptoms for 3 to 5 years and consults 5 or more physicians before receiving an accurate diagnosis. In high-grade NEC, such delays can be devastating.

3. Research Funding Disparity

  • Underfunded Research: Rare cancers account for nearly 25% of all cancer diagnoses and deaths, yet they receive a disproportionately small fraction of federal cancer research dollars.
  • Targeted Non-Profit Support: Foundations like the Neuroendocrine Tumor Research Foundation (NETRF) fill this critical void by funding focused, high-impact clinical and translational studies.

These statistics underscore the vital urgency of our mission. By sharing this data, we demand greater clinical attention, quicker diagnostic pathways, and targeted funding for aggressive carcinomas like the one Ana fought.

Ana Carolina Medina Castillo
Written in Loving Memory

Ana Carolina Medina Castillo

September 5, 1992 – 2026 • Monterrey, MX & Arlington, TX

Registered Nurse (BSN, UT Arlington), devoted mother of Eliana, Elias, and Elaina, and beloved wife of Josue Negron. Her courage and grace continue to guide this platform to ensure no family faces neuroendocrine carcinoma alone.